The dual actions of Paederia scandens extract as a hypouricemic agent: Xanthine oxidase inhibitory activity and uricosuric effect

Planta Medica

Volumn 74, Issue 11, 2008, Pages 1345-1350

  Yan, Haiyan ^a   Ma, Ying ^a   Liu, Mei ^a   Zhou, Lanlan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Hyperuricemia; Paederia scandens extract; Potassium oxonate; Rubiaceae; Serum uric acid; Uricosuric effect; Xanthine oxidase

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CREATININE; PAEDERIA SCANDENS EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; HYPERURICEMIA; IN VIVO STUDY; MALE; NONHUMAN; PAEDERIA SCANDENS; PLANT; RAT; RUBIACEAE; URIC ACID BLOOD LEVEL;

ANIMALS; DRUGS, CHINESE HERBAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RUBIACEAE; URICOSURIC AGENTS; XANTHINE OXIDASE;

PAEDERIA SCANDENS; RATTUS; RUBIACEAE;

EID: 52949087932     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081344     Document Type: Article

References (28)

1. Klemp P, Stansfietd SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-6
2. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabried SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 403-6
3. Liote F. Hyperuricemia and gout. Curr Rheumatol Rep 2003; 5: 27-34
4. Zeng Q, Wang Q, Chen R, Xiao Z, Huang S, Xu J. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J (Engl) 2003; 116: 6-9
5. Li Y, Stornler J, Xiao Z, Folsom A, Tao S, Zhang H. Serum uric acid and its correlates in Chinese adult populations. urban and rural. of Beijing: The PRC-USA collaborative study in cardiovascular and cardiopulmonary epidemiology. Int J Epidemiol 1997; 26: 88-96
6. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 183-90
7. Tseng CH. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med 2005; 21: 24-9
8. Marangella M. Uric acid elimination in the urine: pathophysiological implications. Contrib Nephrol 2005; 147: 32-48
9. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52
10. Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004; 6: 240-7
11. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64: 399-416
12. Liu J, Liang JY, Xie T. Development of iridoids in recent years. Strait Pharm J 2004; 16: 14-8
13. Hiroyuki I, Shuji I, Shimokawa N, Okigawa M. Studies on monoterpene gluclucosides of Paederia scandens. Chem Pharm Bull 1969; 17: 942-8
14. Xu Z, Peng S, Xin L, Bing RB, Ding L. Sulfur-containing iridoid glucosides from Paederia scandens. Fitoterapia 2006; 77: 374-7
15. Stavric B, Clayman S, Gadd REA, Hebert D. Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun 1975; 7: 117-24
16. Hall IH, Scoville JP, Reynolds DJ, Simlot R, Bosisio E. LC-UV-electrospray-MS-MS mass spectrometry analysis of plant constituents inhibiting xanthine oxidase. Pharm Res 1998; 15: 936-43
17. Kong LD, Zhou J, Wen YI, Li JM, Cheng CHK. Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity. Planta Med 2002; 68: 175-8
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-75
19. Kong LD, Cai Y, Huang WW, Cheng CHK, Tan RX. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethno-pharmacol 2000; 73: 199-207
20. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey, 1988-1994. Am J Kidney Dis 2002; 40: 37-42
21. Chen SY, Chen CL, Shen ML, Kamatani N. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism 2001; 50: 1203-7
22. Yale SH, Yale ES, Mann DS. Fever, rash and angioedema after a course of allopurinol. Hosp Pract 1996; 31: 92-4
23. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004; 50: 2400-14
24. Terkeltaub RA. Clinical practice: gout N Engl J Med 2003; 249: 1647-55
25. 25 Yan HY, Ma Y, Liu M, Zhou LL. The effect of Paederia scandens extracts on mouse hyperuricemia induced by yeast. Pharmacol Clin CMM 2007;23: 115-8
26. Hayden MR, Suresh CT. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (London) 2004; 1: 10-25
27. Cohen A, Aberdoth R, Hochstein P. Inhibition of free radical-mediated DNA damage by uric acid. FEBS Lett 1984; 174: 147-50
28. Stinefelt B, Leonard SS, Blemings KP, Shi XL Klandorf H. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid. Ann Clin Lab Sci 2005; 35: 37-45